CHMP recommends adding SURMOUNT-5 to the EU Mounjaro label

European regulators are working through a label update for Mounjaro (tirzepatide) that would place results from a head-to-head trial against semaglutide into the drug's official European Union product information. The European Medicines Agency's procedural record for Mounjaro shows that updates to the Summary of Product Characteristics, the technical label doctors and pharmacists in the EU rely on, go through a formal "Type II variation" process that requires an EMA-led scientific review before a European Commission decision makes the change official ^[1].

The procedural document lists several completed and pending updates to Mounjaro's EU label. One entry shows a Type II variation covering results from a separate cardiovascular outcomes trial, SURPASS-CVOT, which compared tirzepatide against another injectable, dulaglutide, and led to updates in sections 4.1, 4.4, 4.8, and 5.1 of the label ^[1]. Section 5.1 is where the EU label lists a drug's pharmacological and clinical trial data, which is the same section named in the reported development for the semaglutide comparison. The available procedural record does not spell out the specific efficacy numbers, study design details, or exact timeline for the SURMOUNT-5 update by name, so those specifics are not yet confirmed in the documentation reviewed here.

The same EMA record shows Mounjaro's label has been revised multiple times in recent months for reasons unrelated to the semaglutide comparison. These include an extension of the approved indication to children and adolescents ages 10 and older with type 2 diabetes, based on the SURPASS-PEDS study, which prompted updates to sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the label ^[1]. A separate update added breastfeeding guidance after a small lactation study found that tirzepatide levels in breast milk were undetectable to very low compared with levels in the mother's blood following a single 5 mg dose, leading the label to state the drug "could be considered for use during breast-feeding" ^[1].

Why it matters for patients

For patients in the United States, the EU label process described here does not itself change what US doctors prescribe or what the Mounjaro or Zepbound label in the United States says. The EU Summary of Product Characteristics and the US Food and Drug Administration label are separate documents, updated through separate regulatory systems. A change added to the EU label under section 5.1 reflects what European regulators have reviewed and accepted as scientifically supported for use in Europe.

Still, head-to-head trial data comparing two widely used GLP-1 medicines is generally useful information for anyone weighing options with a doctor, since it can show how drugs compare directly rather than only against a placebo. The procedural record confirms that this type of update follows a defined path in the EU: a company submits data, EMA's scientific committees review it, and only after a Commission Decision is issued does the label officially change ^[1]. Until that full process is documented in public records, the exact numbers from the semaglutide comparison, such as how much more or less weight or blood sugar change was seen, are not confirmed in the sources reviewed for this article.

What happens next

The EMA procedural record shows that once a Type II variation is accepted, a European Commission Decision follows, after which the updated Summary of Product Characteristics and Package Leaflet become the official EU label ^[1]. For other recent Mounjaro variations listed in this same record, that step took about six weeks after the scientific outcome was reached ^[1]. Whether or when a similar update tied to the semaglutide comparison will appear in a future version of this procedural document, and what the underlying trial numbers show, is not yet available in the sources reviewed.